Literature DB >> 19757868

Comparing three software tools for implementing markov models for health economic evaluations.

Petra Menn1, Rolf Holle.   

Abstract

BACKGROUND: Various software packages are commonly used for the implementation and calculation of decision-analytic models for health economic evaluations. However, comparison of these programs with regard to ease of implementing a model is lacking.
OBJECTIVES: (i) to compare the assets and drawbacks of three commonly used software packages for Markov models with regard to ease of implementation; and (ii) to investigate how a technical model validation can be conducted by comparing the results of the three implementations.
METHODS: A Markov model on chronic obstructive pulmonary disease was implemented in TreeAge, Microsoft Excel and Arena with the same assumptions on model structure, transition probabilities and costs. A hypothetical smoking cessation programme for patients in stage 1 was evaluated against usual care. The packages were compared with respect to time and effort for implementation, run-time, features for the presentation of results, and flexibility. Agreement between the packages on average costs and life-years gained and on the incremental cost-effectiveness ratio was considered for technical validation in the form of expected values (between TreeAge and Excel only) and Monte Carlo simulations.
RESULTS: Ease of implementation was best in TreeAge, whereas Arena offered the highest flexibility. Deterministic results were in agreement between TreeAge and Excel, as were simulated values between all three packages.
CONCLUSIONS: Excel offers an intuitive spreadsheet interface, but the acquisition of and the training in TreeAge or Arena is worthwhile for more complex models. Double implementation is a practicable validation technique that should be conducted to ensure correct model implementation.

Entities:  

Mesh:

Year:  2009        PMID: 19757868     DOI: 10.2165/11313760-000000000-00000

Source DB:  PubMed          Journal:  Pharmacoeconomics        ISSN: 1170-7690            Impact factor:   4.981


  14 in total

Review 1.  Assessing quality in decision analytic cost-effectiveness models. A suggested framework and example of application.

Authors:  M Sculpher; E Fenwick; K Claxton
Journal:  Pharmacoeconomics       Date:  2000-05       Impact factor: 4.981

Review 2.  Handling uncertainty in cost-effectiveness models.

Authors:  A H Briggs
Journal:  Pharmacoeconomics       Date:  2000-05       Impact factor: 4.981

3.  Validation of health economic models: the example of EVITA.

Authors:  Thomas Hammerschmidt; Anita Goertz; Stefan Wagenpfeil; Albrecht Neiss; Peter Wutzler; Kurt Banz
Journal:  Value Health       Date:  2003 Sep-Oct       Impact factor: 5.725

4.  Alternative decision modelling techniques for the evaluation of health care technologies: Markov processes versus discrete event simulation.

Authors:  Jonathan Karnon
Journal:  Health Econ       Date:  2003-10       Impact factor: 3.046

Review 5.  Good practice guidelines for decision-analytic modelling in health technology assessment: a review and consolidation of quality assessment.

Authors:  Zoë Philips; Laura Bojke; Mark Sculpher; Karl Claxton; Su Golder
Journal:  Pharmacoeconomics       Date:  2006       Impact factor: 4.981

6.  Development of an economic model to assess the cost effectiveness of treatment interventions for chronic obstructive pulmonary disease.

Authors:  Michael Spencer; Andrew H Briggs; Ronald F Grossman; Laureen Rance
Journal:  Pharmacoeconomics       Date:  2005       Impact factor: 4.981

Review 7.  Modelling methods for pharmacoeconomics and health technology assessment: an overview and guide.

Authors:  James E Stahl
Journal:  Pharmacoeconomics       Date:  2008       Impact factor: 4.981

8.  Comparison of Markov model and discrete-event simulation techniques for HIV.

Authors:  Kit N Simpson; Alvin Strassburger; Walter J Jones; Birgitta Dietz; Rukmini Rajagopalan
Journal:  Pharmacoeconomics       Date:  2009       Impact factor: 4.981

Review 9.  Primer on medical decision analysis: Part 4--Analyzing the model and interpreting the results.

Authors:  M D Krahn; G Naglie; D Naimark; D A Redelmeier; A S Detsky
Journal:  Med Decis Making       Date:  1997 Apr-Jun       Impact factor: 2.583

10.  Systematic validation of disease models for pharmacoeconomic evaluations. Swiss HIV Cohort Study.

Authors:  P P Sendi; B A Craig; D Pfluger; A Gafni; H C Bucher
Journal:  J Eval Clin Pract       Date:  1999-08       Impact factor: 2.431

View more
  5 in total

Review 1.  A Comparison of Four Software Programs for Implementing Decision Analytic Cost-Effectiveness Models.

Authors:  Chase Hollman; Mike Paulden; Petros Pechlivanoglou; Christopher McCabe
Journal:  Pharmacoeconomics       Date:  2017-08       Impact factor: 4.981

Review 2.  Verification of Decision-Analytic Models for Health Economic Evaluations: An Overview.

Authors:  Erik J Dasbach; Elamin H Elbasha
Journal:  Pharmacoeconomics       Date:  2017-07       Impact factor: 4.981

3.  Cost effectiveness of an intervention focused on reducing bathing disability.

Authors:  Magnus Zingmark; Ingeborg Nilsson; Fredrik Norström; Klas Göran Sahlén; Lars Lindholm
Journal:  Eur J Ageing       Date:  2016-11-28

4.  A lifetime Markov model for the economic evaluation of chronic obstructive pulmonary disease.

Authors:  Petra Menn; Reiner Leidl; Rolf Holle
Journal:  Pharmacoeconomics       Date:  2012-09-01       Impact factor: 4.558

5.  Modelling long-term cost-effectiveness of health promotion for community-dwelling older people.

Authors:  Magnus Zingmark; Fredrik Norström; Lars Lindholm; Synneve Dahlin-Ivanoff; Susanne Gustafsson
Journal:  Eur J Ageing       Date:  2019-02-23
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.